万古霉素与利奈唑胺治疗耐甲氧西林金黄色葡萄球菌肺部感染的成本-效果分析  

Cost-Effectiveness Analysis of Vancomycin and Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus Pulmonary Infection

作　　者：李曼 谢宁 沈毅 唐扣明 LI Man;XIE Ning;SHEN Yi;TANG Kouming(Department of Pharmacy,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai,China 201700)

机构地区：[1]复旦大学附属中山医院青浦分院药剂科,上海201700

出　　处：《中国药业》2022年第16期107-109,共3页China Pharmaceuticals

基　　金：上海市临床药学重点专科建设项目[沪卫计药政〔2018〕9号];上海市青浦区卫生健康委员会科研课题[W2020-07];上海市青浦区学科带头人培养项目[WD2019-38];上海市青浦区医苑新星培养项目[WY2019-23]。

摘　　要：目的分析万古霉素与利奈唑胺治疗耐甲氧西林金黄色葡萄球菌(MRSA)引起的肺部感染的临床疗效及成本-效果。方法选取医院2015年3月至2020年3月收治的MRSA肺部感染患者207例,按用药的不同分为万古霉素组(106例)和利奈唑胺组(101例)。采用成本-效果分析法对两组药物的使用进行经济学分析。结果万古霉素组及利奈唑胺组患者用药后的感染指标(C反应蛋白、降钙素原水平及白细胞计数)均降低;利奈唑胺组临床有效率及微生物学有效率均较万古霉素组高(97.03%比96.23%,87.13%比78.30%,P>0.05);利奈唑胺组的药物利用指数为1.00±0.02,显著优于万古霉素组的0.62±0.21(t=-17.873,P=0.000)。结论利奈唑胺治疗MRSA引起的肺部感染时,成本-效果优于万古霉素。Objective To analyze the clinical efficacy and cost-effectiveness of vancomycin and linezolid in the treatment of methicillin-resistant Staphylococcus aureus(MRSA)pulmonary infection.Methods A total of 207 patients with MRSA pulmonary infection admitted to the hospital from March 2015 to March 2020 were selected and divided into the vancomycin group(106 cases)and the linezolid group(101 cases)according to different medication methods.The cost-effectiveness analysis method was used to analyze the pharmacoeconomics of the drugs in the two groups.Results The infection indexes[C-reactive protein(CRP),procalcitonin(PCT)levels and white blood cell count(WBC)]of patients in the vancomycin group and the linezolid group decreased after medication.The clinical efficacy and microbiological efficacy in the linezolid group were higher than those in the vancomycin group(97.03%vs.96.23%,87.13%vs.78.30%,P>0.05).The drug utilization index in the linezolid group was 1.00±0.02,which was significantly better than 0.62±0.21 in the vancomycin group(t=-17.873,P=0.000).Conclusion Linezolid is more cost-effective in the treatment of pulmonary infection induced by MRSA.

关 键 词：万古霉素 利奈唑胺 耐甲氧西林金黄色葡萄球菌 肺部感染 成本-效果分析 

分 类 号：R956[医药卫生—药学]